Body Pharm CJC1295 & Ipamorelin 20 Pen

Body Pharm CJC-1295 & Ipamorelin 20 Pen — Order Now on JCSG.org

The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a pre-mixed, multi-dose research-format pen that pairs a short-acting GHRH analogue (CJC-1295 No DAC) with the selective GHS-R1a agonist Ipamorelin in a single sealed cartridge. Available now on JCSG.org — see the current price in the buy box above and add it to your cart today. Supplied for in vitro laboratory use only. Under 2026 MHRA practice, both peptides remain prescription-only, unlicensed medicinal products when presented for human use [7].

For UK researchers, the practical question is not whether the pharmacology works on paper — it is whether this format suits your protocol. Format-level scrutiny matters more than another mechanism explainer. Cost per dose, dose reproducibility, cold-chain handling, and legal exposure are the variables worth examining. This guide scores the 20 Pen against lyophilised vial blends on five criteria, then maps the dosing conventions and side-effect profile worth knowing before you order.

Order the Body Pharm CJC-1295 & Ipamorelin 20 Pen on JCSG.org →

Key takeaways

• The Body Pharm 20 Pen delivers fixed metered doses — verify the per-actuation µg figure against the physical label before any cost-per-dose comparison.
• CJC-1295 No DAC (short half-life) pairs with Ipamorelin to preserve pulsatile GH release rather than tonic stimulation.
• No peer-reviewed 2023–2026 human trial has measured the combination prospectively; all reported benefits extrapolate from pre-2020 single-agent work.
• Both peptides are prescription-only, unlicensed medicinal products under MHRA classification; lawful UK supply is limited to in vitro research use.
• Lyophilised vials offer lower cost per milligram and longer pre-use shelf life; the pen wins on dosing precision and reconstitution simplicity.
• JCSG.org stocks the Body Pharm 20 Pen with batch-specific COA — order now and receive it with full documentation.

Last updated: October 2026.

Body Pharm CJC-1295 & Ipamorelin 20 Pen at a glance

The Body Pharm 20 Pen is a pre-mixed, multi-dose research pen combining CJC-1295 (No DAC) and Ipamorelin in a single barrel, calibrated to deliver 20 metered doses per device and sold in the UK for in vitro laboratory use only. Exact micrograms per click should be verified against the physical label before any study design. See the buy box above for the current price on JCSG.org.

CJC-1295 No DAC is a short-acting GHRH (Growth Hormone-Releasing Hormone) analogue with a half-life measured in minutes to a few hours. It lacks the albumin-binding moiety that extends circulation time [13]. Ipamorelin is a selective GHS-R1a (Growth Hormone Secretagogue Receptor 1a) agonist reported across pre-2020 human pharmacology to spare ACTH (adrenocorticotropic hormone), cortisol and prolactin at standard research concentrations. This distinguishes it from earlier ghrelin mimetics [13]. The pairing is the most-cited dual GHRH/GHS combination in 2024–2026 research literature. No peer-reviewed combination trial published in 2023–2026 quantifies its joint GH/IGF-1 response in humans [14][19].

Specification summary (verify against label)

For deeper pharmacology context, see the CJC-1295 overview. Readers comparing GHRH analogues beyond this blend may also want the Tesamorelin profile.

Why order the Body Pharm 20 Pen from JCSG.org?

JCSG.org is the dedicated UK storefront for Body Pharm research peptides. Every order ships with a batch-specific Certificate of Analysis showing HPLC purity (typically ≥98%) and mass spec confirmation. UK-based dispatch reduces Border Force exposure, and the buy box above always shows the live, current GBP price — no hidden fees, no account-gated pricing. Add to cart now and lock in today's price.

The Body Pharm 20 Pen is manufactured to the same quality standard as the wider Body Pharm pre-mixed pen range. For independent manufacturer details, see bodypharm.co.uk.

Pen vs vial: 5-criteria comparison (2026)

For a UK researcher choosing between the Body Pharm 20 Pen and a lyophilised CJC-1295/Ipamorelin vial blend, the pen wins on convenience, dosing repeatability and cold-chain simplicity. Each actuation delivers a fixed volume without operator calculation. Lyophilised vials win on shelf life before reconstitution, flexibility of concentration, and (usually) lower cost per milligram in 5 mg or 10 mg formats. The powder remains stable for months unopened. The right pick depends on whether your protocol needs fixed micro-actuations or variable concentrations. Both formats are available on JCSG.org — order now.

Side-by-side comparison

Decision rule

Pick the pen if your protocol uses a single fixed concentration across a short study window, you want to minimise reconstitution error, and the per-dose premium is acceptable for a 20-actuation device. Pick lyophilised vials if you need variable concentrations, longer pre-use shelf life, or lower cost per milligram for extended in vitro series. Order whichever format suits your protocol on JCSG.org — current prices are live in the buy box above. For the underlying pharmacology context behind either format, see the CJC-1295 overview. Researchers benchmarking against longer-acting GHRH analogues can cross-reference the Tesamorelin profile.

How CJC-1295 and Ipamorelin work together

The blend pushes growth hormone release through two complementary receptor pathways at once. CJC-1295 activates the GHRH receptor on pituitary somatotrophs. Ipamorelin agonises the ghrelin receptor (GHS-R1a) on the same cell population [10][11].

The two receptors couple through partly distinct intracellular signalling cascades. GHRH works via Gs-coupled cAMP elevation; GHS-R1a works via Gq-coupled IP3/DAG (inositol 1,4,5-trisphosphate/diacylglycerol). Simultaneous activation produces a larger GH pulse than either agent alone [10][11]. That effect is described as synergistic in 2025–2026 review summaries. No controlled 2023–2026 peer-reviewed combination trial has confirmed it [10][11][14].

Two CJC-1295 variants, two pharmacokinetic profiles

CJC-1295 comes in two forms with very different behaviour in solution. CJC-1295 with DAC (Drug Affinity Complex) binds albumin and is widely cited as having a plasma half-life of roughly 5–8 days. The albumin-peptide complex circulates longer than the free peptide, producing a sustained elevation in GHRH tone rather than discrete pulses [13][14]. CJC-1295 No DAC (often labelled Mod GRF 1-29) is the non-albumin-binding peptide with a half-life commonly reported in the 30-minute range. This preserves the natural pulsatile pattern of GH release because the peptide clears before the next endogenous GHRH pulse [13][14]. Both figures originate in pre-2020 work. No head-to-head pharmacokinetic study in humans or primates was published between 2023 and 2026 to refresh them [12][13][14].

The Body Pharm pen, like most pre-mixed UK research pens, pairs the No-DAC variant with Ipamorelin specifically because the short GHRH half-life is intended to overlap with each Ipamorelin-driven ghrelin-receptor pulse. This approach avoids flattening the curve into tonic stimulation [6][10]. For deeper background on the GHRH analogue side of this pairing, see the CJC-1295 overview. Researchers comparing pulsatile No-DAC protocols against a longer-acting, clinically licensed GHRH analogue can cross-reference Tesamorelin [14].

Selectivity and the side-effect profile

Ipamorelin's relevance to the blend rests on its receptor selectivity. Secondary literature from 2024–2025 describes Ipamorelin as a selective GHS-R1a agonist that elevates GH with negligible effect on ACTH-driven cortisol or prolactin at standard research concentrations. This contrasts with earlier GHRPs (Growth Hormone-Releasing Peptides) such as GHRP-6 and hexarelin, which activate multiple ghrelin-receptor subtypes and trigger broader endocrine responses [10][11][17].

Those selectivity claims still trace back to pre-2020 human pharmacology. No 2023–2026 trial has re-quantified the cortisol/prolactin comparison [11][17].

Research-context dosage protocols (and their limits)

The 5:5 mg ratio (5 mg CJC-1295 No DAC plus 5 mg Ipamorelin per lyophilised vial) is the dominant UK vendor convention in 2026. It represents a practical middle ground between cost and peptide concentration, and is a commercial packaging norm rather than an MHRA- or clinical-trial-validated protocol. No peer-reviewed 2023–2026 trial has tested that specific ratio in humans.

Pre-mixed pens such as the Body Pharm 20 Pen translate the same ratio into a fixed dose per click. The product page does not state actuation volume or µg-per-click explicitly; Body Pharm's own per-click figure should be verified against the physical label insert supplied with your order from JCSG.org.

The 5:5 convention is vendor-led, not trial-derived

The underlying logic for 100 µg + 100 µg "saturating" research aliquots traces to pre-2020 single-agent pharmacology rather than combination dosing trials. 2024–2026 reviews continue to extrapolate from that older work because no newer human data exists [6][7]. UK researchers comparing protocols can cross-reference the CJC-1295 overview and the licensed-analogue context on the Tesamorelin page before designing in vitro work.

These figures describe what the research literature reports. They are not human-use instructions. No MHRA-authorised dosing schedule exists for either peptide in this combination.

Reported benefits in the research literature

The CJC-1295 + Ipamorelin pairing is studied for four overlapping outcomes: GH/IGF-1 elevation, body composition shifts, lean-mass and recovery effects, and changes to slow-wave sleep. None of these are MHRA-authorised indications. As of 2026 no peer-reviewed human trial has measured the combination prospectively.

GH and IGF-1 elevation

The mechanistic case is the strongest. CJC-1295 acts at the GHRH receptor while Ipamorelin agonises GHS-R1a. 2019-era pharmacology reviews describe the two pathways as complementary rather than redundant because they activate distinct downstream signalling cascades. Older phase 1/2 work on CJC-1295 with DAC reported sustained IGF-1 elevation in healthy adults and GHD (Growth Hormone Deficiency) patients because the albumin-bound form maintains circulating GHRH tone [17]. The deeper receptor pharmacology is covered on the CJC-1295 overview.

Body composition: fat loss and lean mass

Research frames the combination as studied for simultaneous fat reduction and lean-mass support. The effect is attributed to pulsatile GH release rather than a steady supraphysiological elevation, on the basis that pulsatile patterns more closely mimic endogenous secretion and may preserve metabolic flexibility. The 2024 Frontiers in Endocrinology review of GH secretagogues groups Ipamorelin with agents investigated for visceral-fat and lean-mass endpoints; cited human data predate 2020 [19]. UK researchers comparing GHRH-analogue body-composition data may also want the licensed-drug context on the Tesamorelin page. Tesamorelin is the only GHRH analogue with a marketing authorisation for a visceral-fat indication.

Recovery and slow-wave sleep

Recovery claims rest on the GH–IGF-1 axis's role in tissue turnover and protein synthesis. 2026 research write-ups extrapolate from that rather than from controlled recovery trials [12]. Sleep-architecture claims are the thinnest. The 2019 Pituitary review notes that GHRH activity correlates with slow-wave sleep in older single-agent studies because GHRH neurons are active during the sleep-wake transition [2]. Forum and video commentary describing "deeper sleep" on the blend should be read as anecdotal, not as trial evidence.

Side effects and safety considerations

Reported adverse effects of CJC-1295/Ipamorelin in the research literature cluster around four categories:

• Injection-site reactions (redness, transient stinging) because the peptide solution can trigger local inflammatory responses.
• Mild fluid retention, attributed to GH-mediated sodium reabsorption in the kidney.
• A short-lived head-rush or facial flushing in the minutes after administration, attributed to the GHRH-analogue component's effect on vasodilation.
• Occasional paraesthesia (numbness or tingling in the hands) consistent with the GH-mediated soft-tissue effects seen with other secretagogues [6].

Long-term human safety data for the combination is not established.

Chronic elevation of GH and IGF-1, even when driven pulsatily rather than via exogenous somatropin, carries a theoretical risk of reduced insulin sensitivity and impaired glucose tolerance. Sustained GH elevation antagonises insulin signalling. The 2019 Pituitary review of GH secretagogues flags this as the most consistently raised metabolic concern across the class [7]. The 2024 Frontiers in Endocrinology review echoes it without offering new combination data [19]. Long-term side effects are not well characterised for the blend, which is consistent with the published evidence base [11].

Ipamorelin vs older GHRPs

Ipamorelin is a selective GHS-R1a agonist reported to produce minimal ACTH/cortisol and prolactin release at standard research concentrations. It preferentially activates GHS-R1a over other ghrelin-receptor subtypes, distinguishing it from earlier ghrelin mimetics such as GHRP-6 and hexarelin [7][8]. No 2023–2026 human trial has re-quantified this selectivity. The cleaner profile rests on pre-2020 clinical pharmacology rather than fresh data.

Vendor copy occasionally overstates this as "no cortisol or prolactin effect". The more defensible reading is "negligible at the doses studied." For deeper receptor pharmacology see the CJC-1295 overview. For the only GHRH analogue with a UK marketing authorisation and a published long-term safety dataset, see Tesamorelin.

UK legal status and ordering in 2026

CJC-1295 and Ipamorelin are not licensed medicines in the UK. They are sold lawfully only as research chemicals for in vitro or laboratory use, not for human administration. The MHRA treats peptides that "modify physiological functions by pharmacological action" as medicinal products regardless of "research only" labelling [5][6][7]. Verified October 2026.

No 2024–2026 MHRA notice reclassifies CJC-1295 or Ipamorelin specifically. The 2024 medicines-crime update and the 2024 safety alert on unlicensed injectables make clear that GHRH analogues and GHS peptides fall within the same category as the unlicensed weight-loss injections Border Force has been detaining at UK entry points. Both are prescription-only medicinal products without UK marketing authorisation [5][18]. Importing for personal human use therefore carries seizure and prosecution risk. Acquiring labelled research material for genuine laboratory work does not, provided the supply chain and stated intent are consistent.

JCSG.org supplies the Body Pharm CJC-1295 & Ipamorelin 20 Pen with UK-based dispatch, explicit research-use labelling, and a batch-specific COA. Order now via the buy box above — see the live current price on JCSG.org.

What to check before ordering

UK buyers evaluating the Body Pharm 20 Pen should look for:

• A batch-specific Certificate of Analysis (COA) with HPLC (High-Performance Liquid Chromatography) purity (typically ≥98%) and mass spec confirmation, dated to the lot you receive. JCSG.org supplies this with every order.
• UK-based dispatch and a UK business address, which reduces Border Force exposure relative to EU or Asian shipments. JCSG.org dispatches from within the UK.
• Explicit "research use only, not for human consumption" labelling on both the outer packaging and the device itself.
• A published storage and reconstitution specification — verify the per-actuation payload against the physical label insert before any study design.
• Clear batch and expiry markings consistent across outer carton and cartridge.

For underlying pharmacology see the CJC-1295 overview. For the only GHRH analogue with a UK marketing authorisation, see Tesamorelin. Ready to order? Add to your JCSG.org cart now →

How the Body Pharm 20 Pen fits the UK research peptide range

The 20 Pen sits in the GHRH-analogue plus GHS pillar of a broader UK research peptide range. It shares the same pre-mixed, multi-dose pen format as Body Pharm's Tirzepatide and MOTS-C pens because this geometry simplifies storage and dosing logistics. Researchers planning a multi-arm protocol can treat it as the "combined growth-hormone axis" arm and select adjacent peptides for comparator or complementary work.

For pharmacology depth on the GHRH side of the blend, the CJC-1295 overview covers half-life differences between No-DAC and DAC formats that the pen's short-acting modified GRF (1-29) component sits within [14]. For a GHRH analogue with an actual UK marketing authorisation as a benchmark, Tesamorelin is the natural comparator, particularly for studies modelling visceral adipose tissue or IGF-1 dynamics against an approved standard.

Adjacent peptides in protocol design

MOTS-C is the mitochondrial-derived peptide arm most researchers pair with a GH-axis intervention when metabolic endpoints are in scope. It targets mitochondrial function independently of the GH axis. Body Pharm offers it in the same 20-dose pen geometry, which simplifies storage logistics across a study. BPC-157 and TB500 sit in a different category (tissue-repair research) but commonly appear in the same procurement basket because the same vendor checks — COA, UK dispatch, research-use labelling — apply identically. No published 2023–2026 trial combines all of these in a single protocol. Any multi-peptide design rests on single-agent literature. Browse and order all Body Pharm peptides on JCSG.org →

Frequently asked questions

Is CJC-1295 & Ipamorelin legal to buy in the UK in 2026?

CJC-1295 and Ipamorelin sit in a regulatory grey zone in the UK. As of 2026 the MHRA treats both as prescription-only, unlicensed medicinal products when presented for human use because they modify physiological function by pharmacological action. Lawful UK acquisition is limited to bona fide in vitro research, with no marketing authorisation covering anti-ageing, performance or fat-loss claims [3][5]. JCSG.org supplies these peptides under full research-use labelling and with batch COA documentation.

What's the difference between CJC-1295 DAC and No DAC?

DAC (Drug Affinity Complex) is a maleimidopropionic acid moiety that binds CJC-1295 to serum albumin, extending plasma half-life to roughly 5–8 days. The albumin-peptide complex circulates longer than the free peptide. The No DAC form, structurally equivalent to modified GRF (1-29), clears within minutes to a few hours and produces a sharper, pulsatile GH profile. This more closely mimics endogenous release because the peptide is eliminated before the next natural GHRH pulse [7][8]. See the CJC-1295 overview for half-life data.

How many doses are in the Body Pharm pen?

The product is labelled as a 20-dose pre-mixed pen, with each click intended to deliver a fixed actuation volume from a single sealed cartridge. The exact µg per click depends on the cartridge's total peptide load and click geometry. Verify against the physical packaging insert supplied with your JCSG.org order before any cost-per-dose calculation.

How should the pen be stored?

Pre-mixed CJC-1295/Ipamorelin pens are typically refrigerated at 2–8 °C and used within around 28–30 days of first actuation. Protection from light and freeze-thaw cycles is essential because the pre-mixed solution begins to degrade once the seal is broken and the peptides are exposed to oxidation. The printed insert supplied with your JCSG.org order is the authoritative storage reference [17].

Is the 5:5 ratio standard?

A 1:1 mg ratio (commonly presented as 5 mg + 5 mg in 10 mg vial blends) is the most frequently encountered convention among UK research vendors. It reflects supplier convenience rather than a clinically validated optimum because no human trial has tested the ratio prospectively [10][16]. For a GHRH analogue with an actual UK marketing authorisation as comparator, see Tesamorelin.

Order now — next steps for UK researchers

If you have decided the pre-mixed format fits your protocol, order the Body Pharm CJC-1295 & Ipamorelin 20 Pen directly on JCSG.org — the buy box above shows today's live GBP price and ships with a batch-specific COA. Confirm the µg-per-click figure against the cartridge insert when you receive your order. If your work needs variable concentrations or longer pre-use shelf life, default to a lyophilised 5 mg + 5 mg vial blend — also available on JCSG.org. Cross-reference the CJC-1295 overview and Tesamorelin profile to contextualise your choice against the broader GHRH-analogue literature before finalising your protocol.

Add to cart on JCSG.org now — UK dispatch, batch COA included →

For research use only. Not for human consumption. Supply and possession of unlicensed medicinal products for human use is regulated by the MHRA.